Versantis AG has agreed terms with Genfit SA in an acquisition deal that involves CHF40 million (US$41.4 million) up front, plus up to CHF65 million in milestones, and one third of the proceeds from a potential sale of a rare pediatric disease priority review voucher, should the U.S. FDA grant one.
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Ltd. have launched Radiopharm Ventures LLC, a joint venture (JV) that will develop radiopharmaceutical therapies for cancer. Radiopharm Theranostics owns 51% of shares in the new entity, while MD Anderson owns 49%.
Voronoi Inc. out-licensed its pan-RAF inhibitor program in a deal worth up to $482.2 million with Metis Therapeutics, a company integrating drug discovery and delivery with artificial intelligence and machine learning.
H-Cyte Inc. has completed its acquisition of Jantibody, a novel cancer immunotherapeutic agent that has demonstrated promising efficacy in controlling ovarian cancer and mesothelioma in preclinical models.
Ducentis Biotherapeutics Ltd. has been acquired by Arcutis Biotherapeutics Inc. for up to $400 million, representing a landmark moment for seed investor Lifearc Ventures, which aims to kick-start promising biotechs in the U.K. while giving any investment returns to its parent medical charity.
Arcutis Biotherapeutics Inc. has entered into an agreement to acquire Ducentis Biotherapeutics Inc., a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases.
For privately held Good Therapeutics Inc., founded in 2016 with a platform technology for developing context-dependent therapeutics, the plan had always been to seek a buyer for the first asset to emerge. One came along a little earlier than expected, as Roche Holding AG entered a merger agreement for Good, picking up preclinical-stage PD-1-regulated IL-2 program, in exchange for an up-front cash payment of $250 million.
With a diminishing number of deals in the last month, the gap between deal values this year compared with each of the last two years has shrunk. In August, 2022 deal values were ahead of 2021 by 7% and of 2020 by 2%. Now, in early September, they are ahead of last year by 0.6% and behind 2020 by 3.5%. Volumes, which were down by 23% last month, are now down by 26%.
RSS
